Ambry

Early adopters of clinical sequencing are all taking slightly different approaches — from whole-genome sequencing to exome sequencing to targeted panels — but one of the key hurdles they all face is interpretation and analysis, according to speakers at Cambridge Healthtech Instit

This article has been updated from a previous version to include market research information about Fluidigm from DeciBio.

This story was originally posted on April 20.

Ambry Genetics said today that it has launched genomic research services based on Fluidigm's BioMark HD and Access Array systems.

Ambry Genetics has launched the First-Step Exome test, a sequencing-based test that analyzes the exons and flanking intronic regions of 4,400 genes that are known to be associated with human disease and are defined within the Human Gene Mutation Database.

Ambry Genetics has launched four targeted sequencing-based cancer panels: CancerNext, BreastNext, ColoNext, and OvaNext.

By Monica Heger
As exome sequencing quickly becomes the method of choice for diagnosing rare conditions, a number of academic groups and companies have launched tests in recent months and are reporting their first successes.

This story has been updated to include additional comments from Ambry Genetics and Sigma-Aldrich.
By Justin Petrone

By Monica Heger
2011 will likely be recognized as the year that genome sequencing broke out of the research realm and moved into the clinic.